Subscribe to our Newsletters !!
Drug quality is defined not only how a drug is man
Within the broader context of the pharmaceutical i
The journey and merging of sperm and egg cells is
This year, the Hamburg based life sciences company
For the first time in its chronicle, the pharmaceu
Since it’s an ingredient in so many foods, you h
Dear Readers,Welcome to the latest issue of Microb
The leader of the European Union’s drugs office Guido Rasi said on Monday an underlying authorisation for U.S. pharmaceutical organization Gilead’s remdesivir as a COVID-19 treatment could be conceded in coming days.
The European Medicines Agency (EMA) has just suggested the caring utilization of remdesivir, which permits a medication to be directed to patients even before it has been completely approved.
“It may be that a contingent market authorisation can be given in the coming days,” Rasi told a meeting in the EU Parliament in Brussels.
Aside from remdesivir, Rasi said other potential medications against COVID-19 that might be accessible quick are those dependent on monoclonal antibodies, which can “kill” the new coronavirus (SARS-CoV-2) that causes the ailment COVID-19.
